A multicenter, randomized, open‐label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis
European Journal of Neurology2024Vol. 31(8), pp. e16322–e16322
Citations Over TimeTop 1% of 2024 papers
Jian Yin, Mingming Zhao, Xianhao Xu, Meini Zhang, Zucai Xu, Zunbo Li, Xinyue Qin, Zhuyi Li, Chongbo Zhao, Hongyu Zhou, Ying Ma, Wenfeng Cao, Guoping Wang, Yongzhong Lin, Jizhong Zhang, Xu Zhang, Hongbin Cai, Weidong Qian, Yiqi Wang, Xinghu Zhang, Guangzhi Liu, Jiawei Wang, Wei Qiu, Lianqiu Min, Jing Li, Hui Deng, Lan Chu, Yifan Zhang, Jianmin Fang
Abstract
Telitacicept demonstrated safety, good tolerability and reduced clinical severity throughout the study period. Further validation of the clinical efficacy of telitacicept in gMG will be conducted in an upcoming phase 3 clinical trial.
Related Papers
- → Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies(2021)45 cited
- → Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor(2008)29 cited
- → Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study(2022)4 cited
- [Myasthenia gravis (1). Experimental myasthenia gravis--a tool for the study of the pathogenesis, diagnosis and treatment of myasthenia gravis].(1978)